POLQ抗体;POLQ Antibody—艾普蒂 新品

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human colorectal cancer using P13276(POLQ Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human esophagus cancer using P13276(POLQ Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

POLQ (DNA polymerase theta) is a specialized DNA polymerase involved in an error-prone DNA repair pathway known as theta-mediated end joining (TMEJ), which serves as a backup mechanism for repairing double-strand breaks (DSBs) when canonical repair pathways like homologous recombination (HR) are compromised. Discovered in the early 2000s, POLQ gained attention for its unique ability to mediate microhomology-based DNA repair, often resulting in genomic rearrangements. Its expression is generally low in healthy tissues but upregulated in various cancers, particularly those with defects in HR (e.g., BRCA-mutant cancers), where POLQ supports cancer cell survival by mitigating replication stress and repairing therapy-induced DNA damage.

POLQ antibodies are critical tools for studying its biological roles, including its localization, expression levels, and interaction partners in cancer models. Researchers have linked elevated POLQ levels to poor prognosis, chemoresistance, and radioresistance in cancers such as breast, ovarian, and lung adenocarcinoma. These findings spurred interest in POLQ as a therapeutic target, with inhibitors (including antibody-based strategies) currently in preclinical development. POLQ inhibition is hypothesized to synergize with DNA-damaging therapies or PARP inhibitors, selectively targeting HR-deficient cancers. However, challenges remain in optimizing specificity and minimizing off-target effects. Overall, POLQ antibodies continue to advance both basic research and translational efforts in oncology.